Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor α gene expression via p38 MAPK/CK2 signaling in human breast cancer cells

FASEB Journal

Volumn 25, Issue 10, 2011, Pages 3695-3707

  De Amicis, Francesca ^a   Giordano, Francesca ^a   Vivacqua, Adele ^a   Pellegrino, Michele ^a   Panno, Maria Luisa ^a   Tramontano, Donatella ^b   Fuqua, Suzanne A W ^c   Andò, Sebastiano ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Er ; Promoter; Tamoxifen resistance

Indexed keywords

CASEIN KINASE II; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; HISTONE DEACETYLASE 1; INSULIN RECEPTOR SUBSTRATE 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; NUCLEAR FACTOR Y; PROTEIN P21; PROTEIN P53; RESVERATROL; RNA POLYMERASE II; TRANSCRIPTION FACTOR SIN3A; TRANSCRIPTION FACTOR SP1;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CASEIN KINASE II; CCAAT-BINDING FACTOR; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 1; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIN3 HISTONE DEACETYLASE AND COREPRESSOR COMPLEX; STILBENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80053908619     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.10-178871     Document Type: Article

References (55)

1. Santen, R. J., Song, R. X., Zhang, Z., Kumar, R., Jeng, M. H., Masamura, A., Lawrence, J., Jr., Berstein, L., and Yue, W. (2005) Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr. Relat. Cancer 1, 61-73
2. Cui, Y., Parra, I., Zhang, M., Hilsenbeck, S. G., Tsimelzon, A., Furukawa, T., Horii, A., Zhang, Z. Y., Nicholson, R. I., and Fuqua, S. A. (2006) Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 66, 5950-5959
3. Hutcheson, I. R., Knowlden, J. M., Madden, T. A., Barrow, D., Gee, J. M., Wakeling, A. E., and Nicholson, R. I. (2003) Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res. Treat. 81, 81-93
4. Grunt, T. W., Saceda, M., and Martin, M. B. (1995) Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int. J. Cancer 63, 560-567
5. Encarnacion, C. A., Ciocca, D. R., McGuire, W. L., Clark, G. M., Fuqua, S. A., and Osborne, C. K. (1993) Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treat. 26, 237-246
6. Jordan, V. C., and O'Malley, B. W. (2007) Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J. Clin. Oncol. 25, 5815-5824
7. Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., Metzger, D., and Chambon, P. (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491-1494
8. Hu, X. F., Veroni, M., De Luise, M., Wakeling, A., Sutherland, R., Watts, C. K., and Zalcberg, J. R. (1993) Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int. J. Cancer 55, 873-8769
9. Hong, W. K., and Sporn, M.B. (1997) Recent advances in chemoprevention of cancer. Science 278, 1073-1077
10. Bhat, K. P., and Pezzuto, J. M. (2002) Cancer chemopreventive activity of resveratrol. Ann. N. Y. Acad. Sci. 957, 210-229
11. Mukherjee, S., Dudley, J. I., and Das, D. K. (2010) Dose-dependency of resveratrol in providing health benefits. Dose Response 8, 478-500
12. Tsai, S. H., Lin-Shiau, S. Y., and Lin, J. K. (1999) Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br. J. Pharmacol. 126, 673-678
13. Hsieh, T. C., Burfeind, P., Laud, K., Backer, J. M., Traganos, F., Darzynkiewicz, Z., and Wu, J. M. (1999) Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials. Int. J. Oncol. 15, 245-252
14. Ferry-Dumazet, H., Garnier, O., Mamani-Matsuda, M., Vercauteren, J., Belloc, F., Billiard, C., Dupouy, M., Thiolat, D., Kolb, J. P., Marit, G., Reiffers, J., and Mossalayi, M. D. (2002) Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells. Carcinogenesis 23, 1327-1333
15. Huang, C., Ma, W. Y., Goranson, A., and Dong, Z. (1999) Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 20, 237-242
16. Bowers, J. L., Tyulmenkov, V. V., Jernigan, S. C., and Klinge, C. M. (2000) Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141, 3657-3667
17. Scarlatti, F., Sala, G., Somenzi, G., Signorelli, P., Sacchi, N., and Ghidoni, R. (2003) Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J. 17, 2339-2341
18. De Amicis, F., Zupo, S., Panno, M. L., Malivindi, R., Giordano, F., Barone, I., Mauro, L., Fuqua, S. A., and Andò, S. (2009) Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor alpha gene promoter. Mol. Endocrinol. 23, 454-465
19. Vivacqua, A., Lappano, R., De Marco, P., Sisci, D., Aquila, S., De Amicis, F., Fuqua, S. A., Andò, S., and Maggiolini, M. (2009) G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. Mol. Endocrinol. 23, 1815-1826
20. Giordano, C., Cui, Y., Barone, I., Andò, S., Mancini, M. A., Berno, V., and Fuqua, S. A. (2010) Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305. Breast Cancer Res. Treat. 119, 71-85
21. Bunone, G., Briand, P. A., Miksicek, R. J., and Picard, D. (1996) Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15, 2174-2183
22. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K., and Vogelstein, B. (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249, 912-920
23. Moore, L., Lu, X., Ghebranious, N., Tyner, S., and Donehower, L. A. (2007) Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity. Ageing Dev. 128, 717-730
24. Lu, X., Lozano, G., and Donehower, L. A. (2003) Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system. Mutat. Res. 522, 69-83
25. DeGraffenried, L. A., Hilsenbeck, S. G., and Fuqua, S. A. (2002) Sp1 is essential for estrogen receptor alpha gene transcription. J. Steroid. Biochem. Mol. Biol. 82, 7-18
26. Panno, M. L., Giordano, F., Palma, M. G., Bartella, V., Rago, V., Maggiolini, M., Sisci, D., Lanzino, M., De Amicis, F., and Andò, S. (2009) Evidence that bergapten, independently of its photo-activation, enhances p53 gene expression and induces apoptosis in human breast cancer cells. Curr. Cancer Drug Targets 9, 469-481
27. Azios, N. G., Krishnamoorthy, L., Harris, M., Cubano, L. A., Cammer, M., and Dharmawardhane, S. F. (2007) Estrogen and resveratrol regulate Rac and Cdc42 signaling to the actin cytoskeleton of metastatic breast cancer cells. Neoplasia 9, 147-158
28. Gartel, A. L., and Radhakrishnan, S. K. (2005) Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 65, 3980-3985
29. Akiyama, T., Ohuchi, T., Sumida, S., Matsumoto, K., and Toyoshima, K. (1992) Phosphorylation of the retinoblastoma protein by cdk2. Proc. Natl. Acad. Sci. U. S. A. 89, 7900-7904
30. Laptenko, O., and Prives, C. (2006) Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 13, 951-961
31. Duval, D., Malaisé M, Reinhardt, B., Kedinger, C., and Boeuf, H. (2004) A p38 inhibitor allows to dissociate differentiation and apoptotic processes triggered upon LIF withdrawal in mouse embryonic stem cells. Cell Death Differ. 11, 331-341
32. Liu, G., Schwartz, J. A., and Brooks, S. C. (1999) p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE. Biochem. Biophys. Res. Commun. 264, 359-364
33. Guvakova, M. A., and Surmacz, E. (1997) Tamoxifen interferes with the insulin-like growth factor I receptor signaling pathway in breast cancer cells. Cancer Res. 57, 2606-2610
34. Smith, C.L., Nawaz, Z., and O'Malley, B.W. (1997) Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 11, 657-666
35. Zilfou, J. T., Hoffman, W. H., Sank, M., George, D. L., and Murphy, M. (2001) The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol. Cell. Biol. 21, 3974-3985
36. Shirley, S. H., Rundhaug, J. E., Tian, J., Cullinan-Ammann, N., Lambertz, I., Conti, C. J., and Fuchs-Young, R. (2009) Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res. 69, 3405-3414
37. Ho, J., and Benchimol, S. (2003) Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ. 10, 404-408
38. Sun, J. M., Chen, H. Y., and Davie, J. R. (2007) Differential distribution of unmodified and phosphorylated histone deacetylase 2 in chromatin. J. Biol. Chem. 282, 33227-33236
39. Pluemsampant, S., Safronova, O. S., Nakahama, K., and Morita, I. (2008) Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors. Int. J. Cancer 122, 333-341
40. Hildesheim, J., Salvador, J. M., Hollander, M. C., and Fornace, A. J., Jr. (2005) Casein kinase 2- and protein kinase A-regulated adenomatous polyposis coli and beta-catenin cellular localization is dependent on p38 MAPK. J. Biol. Chem. 280, 17221-17226
41. Faniello, M. C., Bevilacqua, M. A., Condorelli, G., deCrombrugghe, B., Maity, S. N., Avvedimento, V. E., Cimino, F., and Costanzo, F. (1999) The B subunit of the CAAT-binding factor NFY binds the central segment of the co-activator p300. J. Biol. Chem. 274, 7623-7626
42. Imbriano, C., Gurtner, A., Cocchiarella, F., Di Agostino, S., Basile, V., Gostissa, M., Dobbelstein, M., Del Sal, G., Piaggio, G., and Mantovani, R. (2005) Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol. Cell. Biol. 25, 3737-3751
43. Fontecave, M., Lepoivre, M., Elleingand, E., Gerez, C., and Guittet, O. (1998) Resveratrol a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 421, 277-279
44. Zheng, J., and Ramirez, V. D. (2000) Inhibition of mitochondrial proton F0F1- ATPase/ATP synthase by polyphenolic phytochemicals. Br. J. Pharmacol. 130, 1115-1123
45. Stewart, J. R., Christman, K. L., and O'Brian, C. A. (2000) Effects of resveratrol on the autophosphorylation of phorbol esterresponsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation, Biochem. Pharmacol. 60, 1355-1359
46. Ciolino, H. P., Yeh, G. C. (1999) Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol. Pharmacol. 56, 760-767
47. Frech, M. S., Halama, E. D., Tilli, M. T., Singh, B., Gunther, E. J., Chodosh, L. A., Flaws, J. A., and Furth, P. A. (2005) Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res. 65, 681-685
48. Holst, F., Stahl, P. R., Ruiz, C., Hellwinkel, O., Jehan, Z., Wendland, M., Lebeau, A., Terracciano, L., Al-Kuraya, K., Janicke, F., Sauter, G., and Simon, R. (2007) Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat. Genet. 39, 655-660
49. Lin, H. Y., Lansing, L., Merillon, J. M., Davis, F. B., Tang, H. Y., Shih, A., Vitrac, X., Krisa, S., Keating, T., Cao, H. J., Bergh, J., Quackenbush, S., and Davis, P. J. (2006) Integrin alphaVbeta3 contains a receptor site for resveratrol. FASEB J. 20, 1742-1744
50. Yu, C. L., Driggers, P., Barrera-Hernandez, G., Nunez, S. B., Segars, J. H., and Cheng, S. (1997) The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. Biochem. Biophys. Res. Commun. 239, 617-620
51. Levesque, M. A., Diamandis, E. P., Yu, H., and Sutherland, D. J. (1994) A quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. Breast Cancer Res. Treat. 30, 179-195
52. Diel, P. (2002) Tissue-specific estrogenic response and molecular mechanisms. Toxicol. Lett. 127, 217-224
53. Smith, C. L., and O'Malley, B. W. (2004) Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25, 45-71
54. Jepsen, K., Hermanson, O., Onami, T. M., Gleiberman, A. S., Lunyak, V., and Rosenfeld, M. G. (2000) Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102, 753-776
55. Castles, C. G., Oesterreich, S., Hansen, R., and Fuqua, S. A. (1997) Auto-regulation of the estrogen receptor promoter. J. Steroid. Biochem. Mol. Biol. 62, 155-163